Epitel
Epitel develops the REMI Remote EEG Monitoring System, a wearable wireless EEG recording platform for epilepsy monitoring and seizure detection in healthcare facility and ambulatory settings. The system uses only four truly wireless sensors that transmit single-channel electrical brain activity data to the REMI Cloud via a mobile application, enabling near real-time remote review on qualified EEG viewing software…
Funding snapshot
About
Epitel develops the REMI Remote EEG Monitoring System, a wearable wireless EEG recording platform for epilepsy monitoring and seizure detection in healthcare facility and ambulatory settings. The system uses only four truly wireless sensors that transmit single-channel electrical brain activity data to the REMI Cloud via a mobile application, enabling near real-time remote review on qualified EEG viewing software including Persyst Mobile. REMI Vigilenz AI for Event Detection provides automated annotation of potential electrographic seizure activity with confidence levels and duration markings, aiding qualified physicians in EEG review. The disposable, single-patient wearable sensors can monitor for up to 30 days, supporting adult and pediatric patients aged one year and older. The system is reimbursable using preexisting codes and enables EEG monitoring to be initiated within minutes. Founded in 2007 and headquartered in Salt Lake City, Utah, the company has raised approximately $12.5M in Series A funding. Epitel differentiates itself as the only truly wireless EEG system with just four sensors, enabling patient mobility and rapid deployment in both clinical and ambulatory environments.
Business model
Wearable Technology > Health and Wellness Devices > Neural > Epilepsy,
Neurology > Medical Devices > Screening Devices > Electrodiagnostic Testing > Clinic Based > Epilepsy
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.